Prophylaxis for heterotopic ossification after primary total hip arthroplasty. A cohort study between indomethacin and meloxicam.
The authors have conducted a prospective cohort study of the efficacy of a 7 days administration of Indomethacin (n = 89) versus Meloxicam (n = 92), in the prophylaxis of heterotopic ossification (HO) in primary total hip arthroplasty. To assess the interobserver variability of the Brooker classification, all radiographs were evaluated by three investigators. In the Indomethacin group 25 patients developed HO (grade I: 22, grade III: 2 and grade IV: 1). In the Meloxicam group 34 developed HO (grade I: 30, grade II: 1 and grade III: 3). We were not able to show any difference between Indomethacin and Meloxicam in preventing heterotopic ossification after primary hip arthroplasty. We found a high interobserver variability in the grading system according to Brooker, in particular for the higher grades(grade II, III and IV).
van der Heide
Huub J L
HJ
Department of Orthopaedics, Sint Maartenskliniek, Nijmegen, The Netherlands. huub.vanderheide@tiscali.nl
Spruit
Maarten
M
Slappendel
Rob
R
Klooster
Niels
N
van Limbeek
Jacques
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D018890:Chemoprevention / Q000379:methods; D015331:Cohort Studies; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage*; D008297:Male; D000077239:Meloxicam; D008875:Middle Aged; D015588:Observer Variation; D009999:Ossification, Heterotopic / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D013843:Thiazines / Q000008:administration & dosage*; D013844:Thiazoles / Q000008:administration & dosage*; D016896:Treatment Outcome
D016861:Cyclooxygenase Inhibitors; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam; D007213:Indomethacin